Keith A. Goldan

Insider Reports History

Entity
Individual
Location
227 Washington Street, Suite 200, Conshohocken, PA
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Keith A. Goldan:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Syndax Pharmaceuticals Inc Chief Financial Officer Stock Options (Right to buy) 70K $1.56M $22.28 Feb 7, 2024 Direct
Syndax Pharmaceuticals Inc Chief Financial Officer Common Stock 52.6K $1.05M $20.03 Jun 14, 2024 Direct
OptiNose, Inc. Chief Financial Officer Common Stock 142K $163K $1.15 Mar 16, 2022 Direct

Insider Reports Filed by Keith A. Goldan

Symbol Company Period Transactions Value $ Form Type Date Filed Role
SNDX Syndax Pharmaceuticals Inc Jun 14, 2024 1 $25K 4 Jun 17, 2024 Chief Financial Officer
SNDX Syndax Pharmaceuticals Inc Feb 7, 2024 5 $1.6M 4 Feb 9, 2024 Chief Financial Officer
SNDX Syndax Pharmaceuticals Inc Jun 13, 2023 1 -$12.9K 4 Jun 14, 2023 Chief Financial Officer
SNDX Syndax Pharmaceuticals Inc Feb 2, 2023 1 $3.14M 4 Feb 3, 2023 Chief Financial Officer
SNDX Syndax Pharmaceuticals Inc Jun 13, 2022 2 $3.59M 4 Jun 15, 2022 Chief Financial Officer
SNDX Syndax Pharmaceuticals Inc Jun 13, 2022 0 $0 3 Jun 15, 2022 Chief Financial Officer
OPTN OptiNose, Inc. Mar 16, 2022 1 -$9.74K 4 Mar 17, 2022 Chief Financial Officer
OPTN OptiNose, Inc. Jan 11, 2022 3 $0 4 Jan 12, 2022 Chief Financial Officer
OPTN OptiNose, Inc. Dec 16, 2021 1 -$951 4 Dec 17, 2021 Chief Financial Officer
OPTN OptiNose, Inc. Sep 16, 2021 1 -$1.61K 4 Sep 17, 2021 Chief Financial Officer
OPTN OptiNose, Inc. Jun 17, 2021 1 -$2.15K 4 Jun 17, 2021 Chief Financial Officer